ライフサイエンスコーパス: lung transplant

1 ; P=0.002 for liver and HR, 2.42; P=0.01 for lung transplants).

2 dity and mortality among patients undergoing lung transplant.

3 ronchiolitis obliterans, and rejection after lung transplant.

4 biome changes with disease exacerbations and lung transplant.

5 ilitated by pseudomonas infection and single lung transplant.

6 is similar to findings in humans with acute lung transplant.

7 well as improved function of the allogeneic lung transplant.

8 d with higher odds of not being accepted for lung transplant.

9 ended intensive care including the option of lung transplant.

10 or clinical outcomes, particularly following lung transplant.

11 esource use during index hospitalization for lung transplant.

12 increased risk of delisting or death before lung transplant.

13 s seems to be an emerging pathogen mainly in lung transplants.

14 t; 58 (17.6%), heart transplant; 54 (16.4%), lung transplant; 34 (10.3%), liver transplant; and 6 (1.

15 Of the 10,545 who underwent a lung transplant, 5179 (49.11%) did so during the day and

16 years; heart transplant, 269,715 life-years; lung transplant, 64,575 life-years; pancreas-kidney tran

17 The primary outcome was acceptance for lung transplant after initial evaluation.

18 neumonia (aHR, 1.8; 95% CI, 1.3-2.3), single lung transplant (aHR, 1.3; 95% CI, 1.0-1.7), and idiopat

19 tistically significant in kidney, liver, and lung transplants, although liver and lung recipients had

20 cause of early morbidity and mortality after lung transplant and is characterized by severe hypoxemia

21 change in mean total hospital charges among lung transplant and other solid-organ transplant recipie

22 Rates for death or double-lung transplant and the composite rates for death, doubl

23 sociation between the center volume of adult lung transplants and 1-year recipient mortality that is

24 Recipients of multivisceral, redo, and lobar lung transplants and those who underwent pretransplant c

25 severity, and potential contraindications to lung transplant, and before or after use of the lung all

26 CMV D+/R- serostatus, lung transplant, and treatment phase viral kinetics were

27 Six patients underwent lung transplant, and two died on the waiting list after

28 s demonstrate that the airways involved in a lung transplant are relatively hypoxic at baseline and t

29 Outcomes following lung transplant are suboptimal owing to chronic allograf

30 Every year, thousands of heart and lung transplants are performed worldwide.

31 tion (100% at 40 HAU and 60% healthy and 61% lung transplant at 160 HAU; P = 1.0; chi-square).

32 plant Outcomes Group who underwent bilateral lung transplant at our institution between 2004 and 2014

33 pectively collected from patients undergoing lung transplants at Duke Hospital.

34 tus of both donor and recipient may identify lung transplants at heightened risk for late-onset cytom

35 Patients who received lung transplants at our institution between January 2004

36 cohort study including recipients of primary lung transplants between 2008 and 2012.

37 rvival were estimated among adults receiving lung transplants between June 2010 and June 2015 based o

38 zithromycin may reduce the incidence of post-lung transplant bronchiolitis obliterans syndrome.

39 prevention of coccidioidal infection in the lung transplant candidate.

40 Frailty is prevalent among lung transplant candidates and is independently associat

41 V infection in donors and kidney, heart, and lung transplant candidates and recipients and recommend

42 ectrum of prior cardiothoracic procedures in lung transplant candidates and the impact of prior proce

43 The prevalence of anti-HLA antibodies in lung transplant candidates and their impact on waitlist

44 These data show that one third of lung transplant candidates do not survive 1 year after t

45 We performed an ecologic study of 12 187 lung transplant candidates listed at 56 U.S. lung transp

46 ied from 1987 to 2013 to identify first-time lung transplant candidates who were tracked from wait li

47 -body dual X-ray absorptiometry in 142 adult lung transplant candidates.

48 dered as a bridge to transplantation for all lung transplant candidates.

49 All lung transplant cases between January 2000 and July 2013

50 s typically considered the primary metric of lung transplant center performance in the United States.

51 We designed a novel lung transplant center performance metric that incorpora

52 d to determine the association between adult lung transplant center volume and 1-year recipient morta

53 is an increasingly important determinant of lung transplant center volume and that policies that imp

54 , and driving time from residence to closest lung transplant center.

55 6 and 2012 at our institution, a high-volume lung transplant center.

56 lung transplant candidates listed at 56 U.S. lung transplant centers between 2006 and 2012.

57 Although most lung transplant centers use antifungal prophylaxis, cons

58 hough case loads vary substantially among US lung transplant centers, the impact of center effects on

59 alveolar lavage (BAL), techniques central to lung transplant clinical practice, provide a unique oppo

60 inal organs by means of EVLP with a standard lung transplant cohort through a multicenter open trial.

61 sortium comprising heart, kidney, liver, and lung transplant cohorts.

62 The lung transplant community continues to struggle with the

63 Five out of six patients (83.3%) receiving a lung transplant could be discharged from hospital.

64 Among R+ lung transplants, D- serostatus was associated with the

65 R, 1.05; 95% CI, 0.91-1.21; P = .47) and for lung transplants during the day were 83.8% vs 82.6% duri

66 R, 1.05; 95% CI, 0.88-1.26; P = .59) and for lung transplants during the day were 92.7% vs 91.7% duri

67 idence interval, 0.83-1.32; P = .67) and for lung transplants during the day were 96.0% vs 95.5% duri

68 n Patient registry who underwent their first lung transplant evaluation between 2001 and 2009.

69 re is no evidence of inferior outcomes after lung transplant from brain-dead donors who have had a pe

70 ry remains a major contributor to early post-lung transplant graft dysfunction and mortality.

71 ations, an intervention was necessary in the lung transplant group compared to 32% (n = 79/245) in th

72 Double-lung transplants had a time-varying association with gra

73 on, recipients of a kidney, liver, heart, or lung transplant have an increased risk for diverse infec

74 nced a higher odds of not being accepted for lung transplant in multivariate analysis.

75 with experience of performing more than 170 lung transplants in the first 5 years of the lung alloca

76 All recipients of kidney, liver, heart, and lung transplants in the United Kingdom between 1987 and

77 tween C57BL/6J and DBA/2J) (Haplotype H2b/d) lungs transplanted into DBA/2J (H2d) recipients were ide

78 Central airways stenosis (CAS) after lung transplant is a poorly understood complication.

79 lity and morbidity among the patients on the lung transplant list.

80 transplant waiting list and 17 on heart and lung transplant list.

81 e of hepatitis C virus (HCV) infection among lung transplant (LT) recipients is 1.9%.

82 miR-16 and miR-195 levels were also noted in lung transplant (LTx) patients with DSA compared with LT

83 ated hemoglobin [HbA1c]) and survival in all lung transplant (LTx) recipients and those with either p

84 humidified high flow nasal cannula (HFNC) in lung transplant (LTx) recipients readmitted to intensive

85 ly improve short- and long-term outcomes for lung transplant (LTx) recipients.

86 eae was performed in heart transplant (HTx), lung transplant (LTx), and mechanical circulatory suppor

87 e examined in vivo using an orthotopic mouse lung transplant model and in vitro using isolated bone m

88 conclusion, we have developed an orthotopic lung transplant model in the ferret with documented long

89 In an in vivo mouse orthotopic lung transplant model of BOS, antagonism of the LPA rece

90 tibility complex-mismatched mouse orthotopic lung transplant model, we investigated a conditioning re

91 accelerates tissue damage and increases post-lung transplant mortality in cystic fibrosis patients.

92 s], 2 kidney transplants [n=164 patients], 3 lung transplants [n=110 patients], and 1 liver transplan

93 for aGVHD was not detected in the plasma of lung transplant or nontransplant sepsis patients.

94 in FiO2; 95% CI, 1.0-1.2; P = 0.01); single lung transplant (OR, 2; 95% CI, 1.2-3.3; P = 0.008); use

95 efined as time to death, acute exacerbation, lung transplant, or decrease in forced vital capacity (F

96 nt and the composite rates for death, double-lung transplant, or restenosis at 36 months were 5% and

97 pportunities to ultimately improve long-term lung transplant outcome.

98 recipients from the multicenter, prospective Lung Transplant Outcomes Group cohort enrolled between J

99 iation study of the multicenter, prospective Lung Transplant Outcomes Group cohort.

100 ontrol study, nested within the multi-center Lung Transplant Outcomes Group cohort.

101 2011, and plasma leptin and mortality in 599 Lung Transplant Outcomes Group study participants.

102 etrospective cohort study of patients in the Lung Transplant Outcomes Group who underwent bilateral l

103 ed between March 2002 and December 2010 (the Lung Transplant Outcomes Group).

104 mokines may interact to negatively influence lung transplant outcomes.

105 mains an important goal to improve long-term lung-transplant outcomes.

106 coronary artery disease (Mod-CAD) undergoing lung transplant, outcomes are not well defined.

107 treatment phase viral kinetics (P = 0.005), lung transplant (P = 0.002), CMV donor (D)+/recipient (R

108 P = 1.0) and at 160 HAU (24% healthy and 36% lung transplant; P = 0.40) were observed.

109 tection rates at 40 HAU (95% healthy and 97% lung transplant; P = 1.0) and at 160 HAU (24% healthy an

110 orya pseudofischeri infection in a bilateral lung transplant patient with cystic fibrosis.

111 cted from patients with BOS (n = 10), stable lung transplant patients (n = 18), and healthy aged-matc

112 lected from patients with BOS (n=10), stable lung transplant patients (n=18) and healthy aged-matched

113 uggest that MMF is present in the airways of lung transplant patients and might affect the structural

114 itamin D deficiency is present in 47% of our lung transplant patients and seems independently associa

115 >/=2% is associated with poor outcome in our lung transplant patients as demonstrated by worse CLAD-f

116 ected in the bronchoalveolar lavage fluid of lung transplant patients diagnosed with IA that received

117 ec [FEV(1)] %predicted) were measured in 131 lung transplant patients during their yearly posttranspl

118 are elevated in bronchoalveolar lavage from lung transplant patients prior to diagnosis of bronchiol

119 e (AUC) for each biomarker in the BALF of 40 lung transplant patients who had at least four samples o

120 bronchoalveolar lavage fluid and plasma from lung transplant patients with and without PGD.

121 Thirty-six of 71 (51%) phase 1 cases were lung transplant patients with positive respiratory cultu

122 For lung transplant patients, a case-control study was perfo

123 kidney allotransplantation patients and six lung transplant patients.

124 r immunization in 25 healthy controls and 54 lung transplant patients.

125 ne should continue to be a high priority for lung transplant patients.

126 s key mediators of the development of PGD in lung transplant patients.

127 in bronchial epithelial cells isolated from lung transplant patients.

128 sed scores for perceived self care agency in lung transplant patients.

129 te of bronchiolitis and improves survival in lung transplant patients.

130 litis (OB), is the leading cause of death in lung transplant patients.

131 bsequent graft failure in kidney, heart, and lung transplants: patients without antibodies had superi

132 ed a retrospective review of 532 consecutive lung transplants performed at our institution.

133 Solitary kidney, liver, heart, and lung transplants performed between January 1, 2011, and

134 In mouse lung transplants, PFD and deuterated PFD treatment impro

135 arly diagnosis of IFI is questionable in the lung transplant population.

136 arly diagnosis of IFI is questionable in the lung transplant population.

137 a, Celsior solution was used in our clinical lung transplant program.

138 The majority of heart and lung transplant providers in our study sample supports t

139 nt, voluntary, web-based survey of heart and lung transplant providers to assess current practice pat

140 The treatment is complex, but lung transplant provides substantial survival benefit an

141 e of 6 h and of 73 min, respectively) on rat lung transplants receiving aspiration of gastric fluid w

142 Longitudinal posttransplant monitoring of a lung transplant recipient (A2, CMV seropositive) who rec

143 Two temporal lung transplant recipient cohorts identified by joinpoin

144 omonas isolates and airway samples from a CF-lung transplant recipient during two years, and followed

145 rst donor-derived C. auris transmission in a lung transplant recipient.

146 thod to sequencing of cfDNA in the plasma of lung transplant recipients (40 samples, six patients).

147 ssociated with treatment among the colonized lung transplant recipients (8/12 [67%] vs 3/25 [12%] who

148 s not associated with increased mortality in lung transplant recipients (9/43 [20.9%] in infected die

149 Cystic fibrosis-lung transplant recipients (CF-LTRs) may be at greater r

150 n (CLAD) is the major outcome limitation for lung transplant recipients (LTR) after the first year, a

151 longitudinal study cohort of 63 consecutive lung transplant recipients (LTR) with a median follow-up

152 maintenance of CMV-specific T cell memory in lung transplant recipients (LTRs) is critical for host d

153 Lung transplant recipients (LTRs) mismatched for CMV (do

154 ACR) in the bronchoalveolar lavage (BAL) of lung transplant recipients (LTRs) to determine the assoc

155 In lung transplant recipients (LTRs), human cytomegalovirus

156 solid organ transplantation, particularly in lung transplant recipients (LTRs).

157 techniques in a large contemporary cohort of lung transplant recipients (LTRs).

158 oietic cell transplantation, particularly in lung transplant recipients (LTRs).

159 with development of AR and BOS in pediatric lung transplant recipients (LTxR).

160 retrospectively analyzed serum samples from lung transplant recipients (n = 108) for antibodies to s

161 in B lipid complex every 24 hr for 4 days in lung transplant recipients achieved amphotericin B conce

162 V) replication and disease commonly occur in lung transplant recipients after stopping anti-CMV proph

163 the single most important cause of death in lung transplant recipients after the first postoperative

164 sion of FoxP3 by flow cytometry in 14 stable lung transplant recipients and 6 lung transplant recipie

165 y artery disease has a high prevalence among lung transplant recipients and has historically been a c

166 ains a serious postoperative complication in lung transplant recipients and is associated with signif

167 rflow obstruction that affects a majority of lung transplant recipients and limits long-term posttran

168 cer-specific survival were noted between non-lung transplant recipients and nontransplant patients.

169 Lung transplant recipients are among those with the high

170 Lung transplant recipients are at high risk of invasive

171 The incidence of PML among heart and/or lung transplant recipients at 1 institution was 1.24 per

172 rvival difference between single- and double-lung transplant recipients at 5 years.

173 ral blood mononuclear cell specimens from 39 lung transplant recipients at the time of transplantatio

174 ssessed in sequential cohorts composed of 82 lung transplant recipients before and 83 patients after

175 We performed a cohort study of 106 lung transplant recipients between 2002 and 2006 at the

176 specimens from symptomatic and asymptomatic lung transplant recipients both by culture (using a clin

177 d in bronchoalveolar lavage (BAL) fluid from lung transplant recipients by enzyme-linked immunosorben

178 usly monitors for rejection and infection in lung transplant recipients by sequencing of cell-free DN

179 and posttransplant CLAD and survival in 191 lung transplant recipients consecutively transplanted.

180 Genetic risk profiling of lung transplant recipients could be a promising approach

181 alysis of transbronchial biopsies from human lung transplant recipients demonstrated an association b

182 Our cohort of lung transplant recipients demonstrates a trend of late-

183 Eight of 807 lung transplant recipients developed hyperammonemia synd

184 Respiratory tract microbial communities in lung transplant recipients differ in structure and compo

185 In the cohort of 1528 lung transplant recipients from 12 transplant centers, d

186 A total of 479 lung transplant recipients from arrest/resuscitation don

187 of M. hominis infections were identified in lung transplant recipients from the same thoracic intens

188 ) was increased in bronchoalveolar lavage of lung transplant recipients growing P. aeruginosa (11.5 [

189 Lung transplant recipients had higher bacterial burden i

190 Lung transplant recipients have an increased risk for in

191 ncreased total hospital charges occurred for lung transplant recipients in 2005, corresponding to LAS

192 the primary site of coccidioidal infection, lung transplant recipients in endemic areas remain parti

193 polymorphisms that have been investigated in lung transplant recipients in relation to the devlopment

194 etrospective cohort study of adult heart and lung transplant recipients in the United Network for Org

195 The average age of lung transplant recipients is increasing, and the mix of

196 ion, but the optimal vaccination schedule in lung transplant recipients is unknown.

197 Thus, immunosuppressive strategies for lung transplant recipients need to be tailored based on

198 Historically, most cases of PTLD among lung transplant recipients occurred within the first yea

199 Three lung transplant recipients presented with invasive M. ho

200 PRM is a novel imaging tool for lung transplant recipients presenting with spirometric d

201 their initial LT hospitalization, bilateral lung transplant recipients received 7 to 10 days of mica

202 Two lung transplant recipients receiving immunosuppressive t

203 efits of voriconazole use when prescribed to lung transplant recipients should be carefully weighed v

204 Lung transplant recipients should be routinely assessed

205 We sought to identify genetic variants in lung transplant recipients that are responsible for incr

206 Lung transplant recipients transplanted at a single cent

207 e investigated a single-center cohort of 340 lung transplant recipients undergoing transplant during

208 We assembled a large cohort of lung transplant recipients using 2004 to 2010 Internatio

209 After genetic data quality control, 680 lung transplant recipients were included in the analysis

210 Nine hundred lung transplant recipients were included.

211 Six hundred fifty-four lung transplant recipients were included.

212 Lung transplant recipients were recruited over 12 months

213 Transbronchial biopsies from all lung transplant recipients were reviewed.

214 ngitudinally in bronchoalveolar lavages from lung transplant recipients who developed bronchiolitis o

215 n 14 stable lung transplant recipients and 6 lung transplant recipients who eventually developed BOS.

216 We hypothesized that lung transplant recipients who experience such spirometr

217 In adult lung transplant recipients who have received 3 months of

218 from 30 healthy subjects and 8 kidney and 9 lung transplant recipients who received influenza vaccin

219 eviewed the medical files of 224 consecutive lung transplant recipients who underwent surgery over a

220 tein expression are significantly reduced in lung transplant recipients with BOS compared to BOS-free

221 protein (CCSP), a marker for Clara cells, in lung transplant recipients with BOS, BOS-free patients a

222 ytokine profiles and protein constituents in lung transplant recipients with BOS.

223 Seventeen lung transplant recipients with CARV infection had bronc

224 Eighteen percent (3/17) of lung transplant recipients with ganR-CMV had received <6

225 3, and -4 in bronchoalveolar lavage (BAL) of lung transplant recipients with good outcome and BOS usi

226 se (PRM(PD)) were compared between bilateral lung transplant recipients with irreversible spirometric

227 Three of 6 lung transplant recipients with NTM disease died compare

228 Adult lung transplant recipients with small chests have tradit

229 imilarly good early survival as contemporary lung transplant recipients without early DSA.

230 Among lung transplant recipients, "bronchiolitis obliterans sy

231 pients, 190 liver transplant recipients, 102 lung transplant recipients, 79 heart transplant recipien

232 ore commonly than early-onset CMV disease in lung transplant recipients, and is associated with an in

233 elopment of squamous cell carcinoma (SCC) in lung transplant recipients, by attempting to account for

234 factors for common fungal infections seen in lung transplant recipients, evaluates the clinical effic

235 We studied 328 lung transplant recipients, from January 2006 to July 20

236 We evaluated 194 bilateral lung transplant recipients, identifying 87 individuals w

237 Eighteen lung transplant recipients, median age of 46 years (rang

238 In bronchoalveolar lavage fluid from human lung transplant recipients, NETs were more abundant in p

239 es from healthy subjects, HIV+ subjects, and lung transplant recipients, providing a gradient of incr

240 Posttransplant complications for pediatric lung transplant recipients, similar to complications for

241 Among lung transplant recipients, there was a slightly higher

242 ntially bronchiolitis obliterans syndrome in lung transplant recipients, with a greater propensity fo

243 FVC values were studied among 205 bilateral lung transplant recipients.

244 r the development of cutaneous malignancy in lung transplant recipients.

245 ed with increased risk of SCC of the skin in lung transplant recipients.

246 rm immunological follow up of a cohort of 55 lung transplant recipients.

247 ors associated with CAS in a large cohort of lung transplant recipients.

248 is predictive of subsequent mortality among lung transplant recipients.

249 ve bronchiolitis leading to graft failure in lung transplant recipients.

250 unacceptably high waiting-list mortality for lung transplant recipients.

251 More problematic is pregnancy in lung transplant recipients.

252 ciated with allograft dysfunction, occurs in lung transplant recipients.

253 ve pulmonary disease, but little is known in lung transplant recipients.

254 eotide polymorphisms (SNPs) was performed in lung transplant recipients.

255 bronchoalveolar lavage (BAL) fluid of human lung transplant recipients.

256 ntly higher among PRP for kidney, liver, and lung transplant recipients.

257 plex at 1 mg/kg every 24 hr for 4 days in 35 lung transplant recipients.

258 ted the BG assay for the detection of IFI in lung transplant recipients.

259 c profile of amphotericin B lipid complex in lung transplant recipients.

260 e and guide therapeutic immunosuppression in lung transplant recipients.

261 rophylaxis against invasive aspergillosis in lung transplant recipients.

262 of mold infections in the explanted lungs of lung transplant recipients.

263 the impact of pretransplant sensitization on lung transplant recipients.

264 the association of NTM with mortality among lung transplant recipients.

265 certain the optimal prophylactic strategy in lung transplant recipients.

266 ic mitochondrial cfDNA in the circulation of lung transplant recipients.

267 ased mortality compared with colonization in lung transplant recipients.

268 ts, NTM were most frequently identified from lung transplant recipients.

269 t or treat DQ-dnDSA may improve outcomes for lung transplant recipients.

270 ls, now describes the use mTOR inhibitors in lung transplant recipients.

271 scontinuation rates are particularly high in lung transplant recipients.

272 nic graft failure and long-term mortality in lung transplant recipients.

273 commonly than early-onset CMV disease among lung transplant recipients.

274 three patients (86%) with NTM infection were lung transplant recipients; 18 of 43 (41.8%) were treate

275 ey and pancreas-transplant recipients, and 2 lung-transplant recipients).

276 alent opportunistic infection that occurs in lung-transplant recipients.

277 es against the alpha1(V) chain are linked to lung transplant rejection and atherosclerosis.

278 Incidence rates in lung transplants showed an increase of A. calidoustus (0

279 assess the likelihood of transitioning from lung transplant (state 1) to BOS (state 2), from transpl

280 There is an unmet clinical need to increase lung transplant successes, patient satisfaction and to i

281 Lung transplant survival is limited by obliterative bron

282 rding to the International Society for Heart Lung Transplant system for cellular rejection with immun

283 The primary outcome was the proportion of lung transplants that developed cytomegalovirus infectio

284 and without definitive treatment other than lung transplant to prolong life.

285 unobiology of the lung and the complexity of lung transplant tolerance.

286 ion between frailty and disability using the Lung Transplant Valued Life Activities disability scale.

287 ty-five centers were classified according to lung transplant volume in 2005-2010, with 8,228 adults (

288 nited Kingdom, there are 216 patients on the lung transplant waiting list and 17 on heart and lung tr

289 cohort study of 13,346 adults placed on the lung transplant waiting list in the United States betwee

290 iation was present for heart transplant, and lung transplant was associated with higher mortality.

291 An adverse effect of ECMO at the time of lung transplant was evident in low-volume centers but ab

292 at Medicaid recipients were not accepted for lung transplant were 1.56-fold higher (95% confidence in

293 d for with propensity score analysis, double-lung transplants were associated with better graft survi

294 Two hundred forty-four consecutive lung transplants were evaluated, 131 were included.

295 From January 2003 to August 2009, 593 lung transplants were performed at our institution.

296 lants, one islet transplant and three double lung transplants were performed with primary function.

297 In 2011, 19 pediatric lung transplants were performed, a transplant rate of 34

298 f cytomegalovirus prophylaxis in all at-risk lung transplants; whether cytomegalovirus serostatus can

299 Forty patients (4.1%) underwent lung transplant with 50% postoperative in-hospital morta

300 , it remains an important complication after lung transplant with potentially preventable risk factor